The impact of adverse reactions on adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy in Japan.
Background: Allergen immunotherapy is the only treatment that can achieve remission for allergic diseases. Aims/Objectives: To investigate the three-year adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy at a clinic in Japan and identify factors that inf...
| Publicado en: | Acta Oto-Laryngologica Vol. 144; no. 7/8; pp. 467 - 476 |
|---|---|
| Autor principal: | |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Taylor & Francis Ltd
Jul/Aug2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Background: Allergen immunotherapy is the only treatment that can achieve remission for allergic diseases. Aims/Objectives: To investigate the three-year adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy at a clinic in Japan and identify factors that influence adherence and severe adverse reactions. Material and Methods: In total, 174 patients aged 12 years or older who started sublingual immunotherapy for Japanese cedar pollinosis (n = 72), house dust mite allergy (n = 55), or both (n = 47) between May 2017 and June 2018. Patient age, sex, type of pharmacotherapy used, adverse reactions, blood test results, and duration of continuous treatment were investigated. Results: The three-year treatment continuation rate was 40.8%. Adverse reaction rates were 12.6% for cedar pollinosis and 40.2% for house dust mite allergy. Patients with dose reductions due to severe reactions had lower first-year continuation rates. In the MITICURE® group, patients with severe reactions had significantly higher serum total IgE levels. Severe reactions were more common in MITICURE® patients with seven or more positive antigen types. Conclusions and Significance: Severe adverse reactions reduced early adherence. 过敏原免疫疗法是唯一可以缓解过敏性疾病的治疗方法。 调查日本一家诊所对日本柳杉花粉病和居室尘螨过敏的舌下免疫疗法的三年持续性, 并确定影响持续性和严重不良反应的因素。 2017 年 5 月至 2018 年 6 月期间, 共有 174 名 12 岁或以上的患者开始接受舌下免疫疗法来治疗日本柳杉花粉病(n = 72)、居室尘螨过敏(n = 55)或两者兼有的病症(n = 47)。调查了患者的年龄、性别、所用药物治疗类型、不良反应、血液检查结果和持续治疗时间。 三年治疗持续率为 40.8%。柳杉花粉病的不良反应率为 12.6%, 居室尘螨过敏的不良反应率为 40.2%。因严重反应而减少剂量的患者第一年继续用药率较低。在 MITICURE® 组中, 发生严重反应的患者血清总 IgE 水平明显较高。严重反应在具有七种或更多种阳性抗原类型的 MITICURE® 患者中更为常见。 严重不良反应会降低早期持续性。 |
|---|